NEW ORLEANS — Application of sun protection factor 30 (SPF30) sunscreen prior to exposure to ultraviolet-B (UVB) light delayed melanoma onset in a mouse model of the disease, according to research presented here at the AACR Annual Meeting 2016, April 16-20. These data suggest that the mouse model can be used to identify new, more effective melanoma-preventing agents.
“Over the past 40 years, the melanoma incidence rate has consistently increased in the United States,” said Christin Burd, PhD, an assistant professor in the Department of Molecular Genetics and the Department of Molecular Virology, Immunology & Medical Genetics at The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute. “Sunscreens are known to prevent skin from burning when exposed to UV sunlight, which is a major risk factor for melanoma. However, it has not been possible to test whether sunscreens prevent melanoma, because these are generally manufactured as cosmetics and tested in human volunteers or synthetic skin models.
“We have developed a mouse model that allows us to test the ability of a sunscreen to not only prevent burns but also to prevent melanoma,” continued Burd. “This is a remarkable accomplishment. We hope that this model will lead to breakthroughs in melanoma prevention.”
Burd and colleagues previously reported in Cancer Discovery, a journal of the AACR, the development of this mouse melanoma model. These genetically engineered mice spontaneously develop melanoma about 26 weeks after the chemical 4-hydroxytamoxifen (4OHT) is applied to the skin.
In this new study, Burd and Andrea Holderbaum, a senior undergraduate biology major working in Burd’s laboratory, found that if they exposed the genetically engineered mice to a single dose of UVB light one day after applying 4OHT to the skin, melanomas appeared much more rapidly, and there were many more tumors. “Melanoma-free survival was reduced by 80 percent, to about five weeks,” said Burd.
The researchers then used the mouse model to test the ability of a number of sunscreens labeled SPF30 to prevent melanoma. The sunscreens, which contained a range of UV-blocking agents, were applied to the mice prior to exposure to the UVB light. All the sunscreens delayed melanoma onset and reduced tumor incidence.
“There were some minor differences in melanoma prevention amongst the different SPF30-labeled sunscreens,” said Burd. “However, we later discovered that even though the sunscreens were all marketed as SPF30, some were actually predicted to have a higher rating. For this reason, it is hard to compare the melanoma-preventing capacity of the different sunscreens at this time.”
Burd explained that a major limitation of the study is that the short dose of UVB used in these experiments is equivalent to the amount of UVB exposure a person might experience in a weeklong beach vacation. “Sunscreens were never meant to handle a week’s worth of sun given at one time, and we are working to reduce the UVB dose we use in our studies,” she said.
Burd added that another limitation is that they used only UVB light, which means that the mice were exposed to only a portion of the entire UV spectrum present in sunlight. “We are currently seeking funding to purchase a solar simulator which will better model all wavelengths of sunlight,” she said. “However, funding for these studies can be hard to come by because sunscreens are primarily developed by the cosmetics industry, which has pledged not to use animals in the development of their products.”
This study was funded by Pelotonia, a grassroots cycling event based in Columbus, Ohio, which has raised more than $106 million for cancer research at Ohio State. Burd and Holderbaum declare no conflicts of interest.
Press registration for the AACR Annual Meeting 2016 is free to qualified journalists and public information officers. Click here for more information.
Follow the AACR Annual Meeting 2016 on Twitter: #AACR16